Height Casts 65% Odds That Congress Rolls Back Pharma Discounts
Pharmaceutical manufacturers are lobbying to reverse Medicare Part D discounts before Congress passes its omnibus spending bill by March 23.
By Height Capital Markets’ assessment, the odds are marginally in big pharma's favor. The campaign-leading Pharmaceutical Research and Manufacturers of America boasts a 65-percent chance of victory but still won't emerge entirely unscathed, Height analyst Andrea Harris said in a Wednesday note.
“We believe that if Congress agrees to reverse the changes to the discounts in full or in part, Congress would require a concession from PhRMA in order to offset the budgetary cost of reducing manufacturers' required discounts."
What's The Problem?
February’s Bipartisan Budget Act of 2018 accelerated closure of the Medicare Part D coverage gap by deepening the discount requirements enforced on manufacturers, according to Height Capital Markets. Drugmakers took part of the cost load off Medicare Advantage and the Prescription Drug Plan, which saw their portion of the bill cut from 20 percent and 25 percent, respectively, to just 5 percent.
The new policy will increase manufacturer contributions from 50 percent to 70 percent and is expected to cost the drug industry about $10 billion over a decade.
A Possible Solution
Height expects the industry to pressure a discount reduction from 70 percent to 60 percent.
“We believe it is unlikely PhRMA will convince Congress to reverse the increased discount in full; the $10-billion price tag is too high,” Harris said. “But we do think that, in exchange for other drug pricing policies, lawmakers could scale back the BBA change.”
The anticipated alternative would reduce consumers’ out-of-pocket spending while putting no new pressure on 2019 MA and PDP premiums. Harris foresees retention of the 25-percent beneficiary burden, with MA coverage between 5 percent and 15 percent.
Who Will Be Affected?
The discounts forced on manufacturers would be less than expected but steeper than current rates.
The condition would hurt makers of top-selling Part D drugs, which, according to Height, include Sanofi SA (ADR) (NYSE: SNY), GlaxoSmithKline plc (ADR) (NYSE: GSK), Merck & Co., Inc. (NYSE: MRK), Pfizer Inc. (NYSE: PFE), Eli Lilly and Co (NYSE: LLY), AstraZeneca plc (ADR) (NYSE: AZN), Celgene Corporation (NASDAQ: CELG), Gilead Sciences, Inc. (NASDAQ: GILD), Amgen, Inc. (NASDAQ: AMGN), AbbVie Inc (NYSE: ABBV), Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA), Biogen Inc (NASDAQ: BIIB) and Johnson & Johnson (NYSE: JNJ).
Related Links:
3 Likely Health Care Disruptors In 2018
Analysis: Negative Reaction To Trump's Tariffs Could Make Him More Likely To Act
See more from Benzinga
Oprah Sheds Stake In Weight Watchers, Remains 'Committed' To The Company
Dear Activists: Buying Stock Can Effect More Change Than Selling It
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
